Somewhat Positive News Coverage Somewhat Unlikely to Affect DBV Technologies (DBVT) Stock Price
Media headlines about DBV Technologies (NASDAQ:DBVT) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DBV Technologies earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6500152304896 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
DBV Technologies (NASDAQ:DBVT) traded down 0.14% on Friday, hitting $43.49. 25,355 shares of the stock were exchanged. The stock’s 50 day moving average price is $41.83 and its 200 day moving average price is $36.39. The firm’s market cap is $2.00 billion. DBV Technologies has a 52-week low of $31.87 and a 52-week high of $46.33.
DBVT has been the topic of a number of analyst reports. BidaskClub cut shares of DBV Technologies from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 14th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of DBV Technologies in a research report on Thursday, July 6th. Deutsche Bank AG initiated coverage on shares of DBV Technologies in a research report on Friday, June 23rd. They set a “buy” rating and a $46.00 price objective on the stock. Jefferies Group LLC reiterated a “buy” rating and set a $47.00 price objective on shares of DBV Technologies in a research report on Thursday, June 1st. Finally, Zacks Investment Research upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Monday, April 24th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $48.83.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.